On June 14, 2010 Food and Drug Administration USA (FDA) approved drug Jalyn (dutasteride 0.5 mg and tamsulosin 0.4 mg) for the treatment of benign prostatic hyperplasia (BPH) in men with prostate enlargement.
Dutasteride is an inhibitor of 5α-reductase, tamsulosin is α1-adrenoceptor blocker. The combination
of dutasteride and tamsulosin has been properly studied in patients with BPH and it was shown high effectiveness and safety profile. Dutasteride helps reduce the size of enlarged prostate gland. Tamsulosin lowers the tone of smooth muscles in the prostate gland, prostatic urethra and urogenital passages. By relaxing smooth muscles, tamsulosin relives the symptoms of obstruction and irritation associated with benign prostatic hyperplasia. Vice president, R&D medicine development leader at Glaxo Smith Klein Anne Phillips shows that is the first time when dutasteride and tamsulosin will be available at one capsule. The drug is contraindicated for use in women and children, as well as patients with hypersensitivity to dutasteride or tamsulosin.
Dutaseride is currently available under the name Avodart and Tamsulosin under the name Flomax.
Glaxo Smith Klein expects that Jalyn (dutasteride 0.5 mg and tamsulosin 0.4 mg) will be available at the pharmaceutical market during the second half of 2010.
